Indian drug makers who were searching for a life-line after facing quality lapses, warning letters and import bans from global health regulators have found a silver lining in the form of Latin America (LatAm).
Even as drug exports have been impacted in last two years with India’s biggest importer United States buying about 15% less drugs, LatAm has emerged as the next big market. Pharma Export Promotion Council (Pharmexcil), an export arm under the ministry of commerce and industries, has identified LatAm as one of the most aggressive regions as far as importing Indian drugs is concerned.
LatAm, in total, posted a growth of 36% in exports in the last financial years with Argentina and Brazil taking the charge. The region, which posted a growth of 14% in exports in the last fiscal, was the silver lining as overall drug exports from Indian recorded a growth of a paltry 1 to 1.5% in 2013-14.